Neuromyelitis optica spectrum disorder pathophysiology

Neuromyelitis optica spectrum disorder Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neuromyelitis optica spectrum disorder from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Radiation therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neuromyelitis optica spectrum disorder pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neuromyelitis optica spectrum disorder pathophysiology
CDC on Neuromyelitis optica spectrum disorder pathophysiology
Neuromyelitis optica spectrum disorder pathophysiology in the news
Blogs on Neuromyelitis optica spectrum disorder pathophysiology
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes

Overview

• Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disorder of the central nervous system (CNS). In aquaporin-4 immunoglobulin G-positive disease, NMOSD is primarily an antibody-mediated astrocytopathy rather than a primary disorder of myelin.
• In aquaporin-4 immunoglobulin G-positive NMOSD, pathogenic aquaporin-4 immunoglobulin G (AQP4-IgG) binds extracellular AQP4 epitopes concentrated on astrocytic endfeet at the blood-brain barrier (BBB). Antibody binding initiates complement activation and cellular effector mechanisms, causing primary astrocyte injury followed by inflammatory amplification and secondary injury to oligodendrocytes, myelin, axons, and neurons.
• Neuromyelitis optica spectrum disorder without detectable AQP4-IgG is mechanistically heterogeneous. Patients with myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) who satisfy current criteria are classified as having myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a distinct disease; the pathogenesis of double-seronegative NMOSD remains incompletely defined.

Pathogenesis

• Neuromyelitis optica spectrum disorder pathogenesis is best established for AQP4-IgG-positive disease and comprises loss of immune tolerance, peripheral autoantibody production, access of AQP4-IgG to the CNS, antibody binding to astrocytes, and complement- and leukocyte-mediated tissue injury.

Core pathophysiologic sequence in AQP4-IgG-positive NMOSD

Stage	Principal event	Consequence
1. Loss of tolerance	AQP4-reactive T and B lymphocytes escape immune tolerance; activated B-lineage cells differentiate into AQP4-IgG-producing plasmablasts and plasma cells.	Circulating pathogenic AQP4-IgG is generated.
2. CNS access	AQP4-IgG reaches AQP4-rich astrocytic endfeet at a permissive or disrupted BBB.	Antibody binds extracellular AQP4 epitopes at the gliovascular interface.
3. Astrocyte injury	AQP4-bound immunoglobulin activates the classical complement pathway and engages immunoglobulin receptors on effector leukocytes.	Astrocytes are injured or lysed, with loss of AQP4 and glial fibrillary acidic protein.
4. Inflammatory amplification	Complement fragments, cytokines, neutrophils, eosinophils, macrophages, and activated microglia amplify local injury.	BBB disruption, edema, protease release, oxidative injury, and bystander damage expand the lesion.
5. Secondary neural injury	Loss of astrocytic support and the inflammatory milieu injure oligodendrocytes, myelin, axons, and neurons.	Demyelination, necrosis, axonal loss, and—when severe—cavitation produce permanent disability.

Mechanistic sequence synthesized from human neuropathology, experimental studies, and authoritative reviews.

Target antigen and astrocytic vulnerability

• Neuromyelitis optica spectrum disorder with AQP4-IgG targets AQP4, the principal CNS water channel, which is enriched on astrocyte endfeet facing capillaries, the glia limitans, ependymal surfaces, and cerebrospinal-fluid interfaces.
• Neuromyelitis optica spectrum disorder autoantibodies bind conformational extracellular epitopes on AQP4. AQP4 occurs mainly as the M1 and M23 isoforms; M23-rich tetramers assemble into orthogonal arrays of particles (OAPs), which permit dense antibody clustering and particularly efficient complement activation.
• Neuromyelitis optica spectrum disorder AQP4-IgG is predominantly immunoglobulin G1 (IgG1), an antibody subclass capable of activating complement and engaging immunoglobulin Fc-gamma receptors on immune effector cells.

Loss of immune tolerance and autoantibody production

• Neuromyelitis optica spectrum disorder involves cooperation between AQP4-reactive cluster of differentiation 4-positive (CD4-positive) T-helper cells and B lymphocytes. B-lineage differentiation into plasmablasts and plasma cells produces pathogenic AQP4-IgG, predominantly in the peripheral immune compartment.
• Neuromyelitis optica spectrum disorder is associated with an interleukin-6 (IL-6)-rich immune environment. IL-6 supports plasmablast survival and AQP4-IgG production, favors pro-inflammatory T-helper 17 (Th17) differentiation, and can increase BBB permeability.
• Neuromyelitis optica spectrum disorder loss of tolerance is not fully resolved. A 2024 experimental study showed that thymic B cells can express and present endogenous AQP4 and delete AQP4-reactive T-cell clones; selective loss of AQP4 expression in murine B cells impaired this central-tolerance checkpoint. This is a mechanistic model and has not established a single cause of human NMOSD.

Access to the central nervous system

• Neuromyelitis optica spectrum disorder lesion initiation requires circulating AQP4-IgG to reach astrocytic AQP4. The initiating event that permits entry across the BBB is not fully established; systemic inflammation, cytokine-mediated endothelial permeability, and local barrier disruption may contribute.
• Neuromyelitis optica spectrum disorder frequently affects the area postrema, a circumventricular structure with fenestrated capillaries and a relatively permissive blood–tissue interface. This anatomy may facilitate antibody access locally but does not by itself explain the full lesion distribution.

Antibody- and complement-mediated effector injury

• Neuromyelitis optica spectrum disorder astrocyte injury is driven principally by complement-dependent cytotoxicity, with additional contribution from antibody-dependent cellular cytotoxicity and inflammatory-cell-mediated bystander injury.

Major effector mechanisms in AQP4-IgG-positive NMOSD

Mechanism	Pathophysiologic process	Tissue effect
Complement-dependent cytotoxicity (CDC)	AQP4-bound IgG1 recruits complement component 1q (C1q), activates the classical complement cascade, and generates inflammatory complement fragments and the terminal membrane attack complex (MAC).	Direct astrocyte membrane injury and lysis; chemotaxis and activation of granulocytes and macrophages; complement-mediated bystander injury.
Antibody-dependent cellular cytotoxicity (ADCC)	Natural killer cells, neutrophils, and macrophages engage the constant region of AQP4-bound IgG through Fc-gamma receptors.	Complement-independent astrocyte injury and possible injury to neighboring AQP4-negative cells; considered contributory rather than the dominant mechanism.
Granulocyte and macrophage amplification	Neutrophils and eosinophils accumulate early; macrophages predominate during tissue breakdown and clearance. These cells release proteases, reactive oxygen species, and inflammatory mediators.	Expansion of astrocyte injury, BBB damage, demyelination, necrosis, and axonal injury.
Microglial and astrocytic signaling	Damaged astrocytes, activated microglia, and infiltrating leukocytes generate cytokine and complement-amplification signals.	Propagation of local inflammation and secondary neuronal and oligodendroglial injury; the relative importance of individual pathways remains under investigation.
AQP4 and glutamate-homeostasis disturbance	Antibody-induced AQP4 internalization and associated reduction of excitatory amino acid transporter 2 (EAAT2) have been demonstrated in some experimental systems.	Altered water and glutamate homeostasis is a proposed contributory mechanism; in-vivo findings are inconsistent, and it is less firmly established than complement-mediated injury.

Secondary demyelination and neuroaxonal injury

• Neuromyelitis optica spectrum disorder produces early astrocyte dysfunction or loss, reducing trophic, metabolic, water, ion, and neurotransmitter support for surrounding neural tissue. Oligodendrocyte injury and myelin loss are therefore generally secondary in AQP4-IgG-positive disease.
• Neuromyelitis optica spectrum disorder lesions may extend through gray and white matter and cause axonal spheroids, axonal transection, neuronal loss, necrosis, and cavitation. These destructive changes help explain why a single attack can leave substantial permanent disability.

Anatomical predilection

• Neuromyelitis optica spectrum disorder preferentially injures the optic nerve, spinal cord, area postrema, periependymal brainstem and diencephalic regions, including the hypothalamus, where AQP4-rich astrocytic interfaces are prominent.
• Neuromyelitis optica spectrum disorder lesion distribution is not explained by AQP4 abundance alone. Regional BBB properties, AQP4 isoform and OAP organization, local complement regulation, vascular and meningeal immune access, and the tissue inflammatory microenvironment are likely modifiers; why many peripheral AQP4-expressing organs are spared remains incompletely understood.

AQP4-IgG-negative disease

• Neuromyelitis optica spectrum disorder without AQP4-IgG does not have one established pathophysiologic mechanism. MOG-IgG-positive disease represents MOGAD, in which the principal target is a myelin/oligodendrocyte surface protein rather than astrocytic AQP4.
• Neuromyelitis optica spectrum disorder that is negative for both AQP4-IgG and MOG-IgG is a heterogeneous clinicoradiologic category. No single target antigen, histopathologic pattern, or molecular pathway has been validated for all double-seronegative cases.

Genetics

• Neuromyelitis optica spectrum disorder is a complex, non-Mendelian autoimmune disease; familial aggregation is uncommon, and no single causative variant explains AQP4-IgG-positive disease.
• Neuromyelitis optica spectrum disorder genetic susceptibility is concentrated in immune-regulatory pathways rather than in established pathogenic coding variants of the AQP4 gene. Human leukocyte antigen (HLA) associations differ by ancestry and AQP4-IgG status.
• Neuromyelitis optica spectrum disorder with AQP4-IgG has been associated in White populations with the HLA-DRB1*03:01:01–HLA-DQA1*05:01:01–HLA-DQB1*02:01:01 haplotype and in Black populations with HLA-DRB1*08:04; these are susceptibility associations, not deterministic or diagnostic markers.
• Neuromyelitis optica spectrum disorder AQP4-IgG-positive susceptibility was further defined by a 2026 pan-ancestry genome-wide association study (GWAS), which identified independent major histocompatibility complex (MHC) signals, a complement component 4A (C4A)-associated signal, and a signal in the signal transducer and activator of transcription 4 (STAT4) locus; a tyrosine kinase 2 (TYK2) variant was protective. These findings connect complement biology, antigen presentation, CD4-positive T-cell signaling, and shared systemic-autoimmunity pathways to disease susceptibility but do not establish an individual patient's cause.

Associated Conditions

• Neuromyelitis optica spectrum disorder with AQP4-IgG may coexist with systemic or organ-specific autoimmune disease, including Sjögren syndrome, systemic lupus erythematosus, autoimmune thyroid disease, and myasthenia gravis. This clustering supports shared humoral immune dysregulation but does not show that any associated disease directly causes NMOSD.
• Neuromyelitis optica spectrum disorder genetic sharing with Sjögren syndrome and systemic lupus erythematosus has been demonstrated for C4A- and STAT4-associated risk signals, further supporting overlap with systemic antibody-mediated autoimmunity.

Gross Pathology

• Neuromyelitis optica spectrum disorder gross pathology is most characteristic in severe AQP4-IgG-associated attacks of the optic nerves and spinal cord. Acute lesions may be swollen and softened and may extend across multiple spinal segments, involving both gray and white matter.
• Neuromyelitis optica spectrum disorder destructive lesions may show tissue necrosis and cavitation; chronic lesions may show marked atrophy, gliosis, and residual cavitary tissue loss.

Microscopic Pathology

• Neuromyelitis optica spectrum disorder with AQP4-IgG has a characteristic astrocyte-destructive, complement-rich, perivascular pathology with secondary demyelination and neuroaxonal injury.

Microscopic features of AQP4-IgG-positive NMOSD lesions

Compartment	Characteristic finding	Interpretation
Astrocytes	Loss of AQP4 and glial fibrillary acidic protein (GFAP) immunoreactivity, astrocyte dystrophy, and astrocyte lysis; AQP4/GFAP loss may be evident before or beyond complete myelin loss.	Supports primary astrocytopathy.
Complement and immunoglobulin	Perivascular immunoglobulin and activated-complement deposition in rosette or rim-like patterns. Acute astrocyte-destructive lesions may contain complement component 4d (C4d), complement component 3d (C3d), and the neoantigen of activated complement component 9 (C9neo); terminal C9neo deposition decreases in later stages, whereas C3d and C4d may persist.	Supports antibody-triggered classical complement activation at astrocytic endfeet.
Inflammatory infiltrate	Abundant macrophages with conspicuous neutrophils and eosinophils, particularly in active lesions; lymphocytes and activated microglia are variably present.	Reflects complement-driven recruitment and cellular amplification of injury.
Myelin and oligodendrocytes	Oligodendrocyte loss and extensive demyelination occur within established destructive lesions.	Usually secondary to astrocyte and inflammatory injury in AQP4-IgG-positive NMOSD.
Axons and neurons	Acute axonal injury, axonal spheroids, axonal loss, and neuronal loss may accompany severe lesions.	Explains incomplete recovery after destructive attacks.
Vessels and chronic lesions	Perivascular inflammation, vascular wall thickening, hyalinization or fibrosis, gliosis, necrosis, and cavitation may be present.	Represents chronic remodeling after severe perivascular inflammatory injury.

• Neuromyelitis optica spectrum disorder complement deposition evolves with lesion age. A 2026 neuropathologic study confirmed a consistent perivascular rosette/rim distribution in acute NMOSD astrocyte-lytic lesions and showed that terminal complement deposition becomes less evident in subacute and chronic tissue; absence of terminal complement staining in an older lesion therefore does not negate prior complement-mediated injury.
• Neuromyelitis optica spectrum disorder pathology described above applies most directly to AQP4-IgG-positive disease. Histopathology cannot be assumed to be uniform in AQP4-IgG-negative NMOSD, which remains a heterogeneous category.